Member Info for douve87

Also I concede if/when we get a deal in the billions for just one of our platforms I will take everything back about our bod (and there's no reason why we shouldn't based on results so far). Does anyone know what the 4.1million sells are about they've appeared three times no over the last couple of days (all same time) but if anyone had sold that many I would expected a greater price impact?

That's what I like to hear and I hope you're right. But the way everyone is getting excited about £20million CRUK grant which would not just be for scancell and would be for one specific trial makes me wonder what everyone else is expecting? I appreciate there is a lot of kudos with the grand challenge and it would be recognition for our science but results and recognition dont seem to alter our share price.

Fair point and I hope they don't care about my individual concerns as that would suggest weak management. The longer this goes on though the more expectation grows. At an earlier stage a smaller deal is more acceptable and understandable but if we end up doing all this development and dilution and only end up with an offer of in the tens of millions for scib1 not hundreds of millions or even billions then questions will be asked about the competence of the bod.

Great post Ang gives a plausible explanation as to why mod patent not fully granted yet and why no deals on modi yet. Still struggling to understand why we can't get a deal on scib1 though? I appreciate "everyone waiting for the combi trials" but I would have thought the results to date would have been sufficient especially against others on the market who've secured a deal. I remember when we all expected deals after the phase 1/2 on scib1 and yet we got results but no deal and now we're waiting again. I'm starting to get to the stage in thinking there's 1 of 3 reasons for us to still be in this position: 1) big pharma don't know what they're doing (but happy to gamble on other biotechs) 2) our bod don't know what they're doing with regards the finance and commercial side of the business 3) there's something wrong with our science that we're all missing? Although I'm no scientist I don't think it's the last option and I think it's too simplistic to think the rest of the market and all major pharma don't understand scancell but understand other bios so that leaves the 2nd option.

I admire your positivity I really do and hand on heart I still believe scancell will come good and very good (but this may turn out to be naivety). But I just can't take your view that we're up 20% since the start of the year so we should be pleased as there are few if any substantial long term holders who have that as an average (the only one I know is JC which is another annoyance). And surely you have to agree the BOD have been somewhat foolish or at the very least very premature when RG talked about leaving CH money to spend or when CH talked about monitizing assets in near/short term. After announcements like this and then to have a placing as the next announcement regarding finance seems misleading (kindest way I could put it).

Hopefully I'm wrong but don't suspect share price to change much until after oo is completed. When you know you can get shares for 12p you're not goin to buy at a higher price before hand. Also some people will sell to give funds to buy cheaper. So next 2-3 weeks will be 12p if not lower if we're unlucky. Btw hope this isn't what he meant by monitization assets and will give him benefit of doubt that it wasn't.

I can't disagree with what you say but other biotechs are getting multi billion deals seemingly on lesser science without jumping through all the hoops we seem yo. So it does make you wonder if we will ever get that big deal. Also a lot of people have been speculating biontech could be the first commercial deal but it's not as if they have billions they've just raised 270million themselves. Don't get me wrong as I said earlier the first deal doesn't have to be the best but considering everyone thinks we building ip for a big deal and yet speculating it will be with an exciting but relatively new and small company. I know it can change quickly but doubt they would do a placing if they expected an influx of cash from monetizing assets in the near term so feel a little cheated by the bod.

If that's CH's definition of near term we ne need to get him a dictionary.

My issue is the elephant hasn't gone. In less then a years time it will be back and bigger then ever (at best it's temporarily hiding or gone outside briefly lol). All today's placing is for to continue modi development, continue clinical work I thought was fully covered by CRUK and commence/start not complete a scib2 study in the us. Don't get me wrong this is all great stuff and considering the spend other biotechs have I think scancell have done amazing but as we've all said a lack of commercial deals/funding is holding the share price down which in turn makes it harder to raise funds. All the great announcements we've had this year and we've only briefly been as high as 19p. As soon as we have a commercial deal that finally gets rid of the elephant, then our share price will start to reflect the science but until then we're trapped under 20p. Even if the first commercial deal isn't the best as long as its enough to give certainty to the market that we have enough to complete out clinical studies then we will fly.

Looks to be a disappointing end to the day share price wise. Ultimately there are a lot of positives here but when there are so many deals going on in the market it's extremely frustrating to see us keep being missed especially when our science is so strong. Makes you wonder if we're (the shareholders) missing something. Onwards and upwards and hopefully by the end of the year this price will be nothing but a memory.

Disappointed by today's announcement and i feel a little mislead when the bod lasted stated they expected to start monetizing our assets in the near to short term, and then the next announcement is the complete opposite, an oo. I also believe the bod had stated that they expected future funding to come from partnerships/deals I appreciate this was never a guarantee but is still disappointing to be in the position again. I know the bod is limited on how much more they can issue but annoyed with the size of the raising. I'd personally prefer they did one large raising that would fully satisfy the trial costs and truly put us in a powerful position instead in 3months time funding will be brought up again. I know hindsight is a wonderful thing but thing but think how much better it would have been if they have done when they announced modi discovery at that share price. Also a little confused as the rns states that some of the money will be used to support CRUK scib2 study? I thought part of the benefit of CRUK taking over the study is that we wouldn't need to? Lastly Lastly I notice the rns makes no mention of the isa pharma payment (so that's still a mystery)? Anyone who can answer the 2 above questions or has any views would be much appreciated. On the positive side I have no intention of selling as still convinced by the science of the 2 established platforms (don't know enough about new one) But im excited by the additional platform and feel it does suggest that we really are aiming to be a powerhouse in the sector and further exemplifies the bod''s change of plan for scancell which was all instigated by the modi discovery. I'm impressed by the strength of our ip and the fact we own it all and am convinced it will pay out eventually (the eventually just keeps getting longer frustratingly).